JHVEPhoto/iStock Editorial via Getty Images Novo Nordisk ( NVO ) said that ocedurenone, under investigation for uncontrolled hypertension in chronic kidney disease patients, missed its primary endpoint in a phase 3 trial. That endpoint was change in systolic blood pressure from baseline to week 12. As a result, the Danish pharma is ending the trial and will also incur an impairment charge of ~DKK 5.
7B (~$816.5M). This will lead to an estimated negative impact of around six percentage points on operating profit growth at constant exchange rates this year compared to what was outlined in Novo's Q1 financial report.
More on Novo Nordisk Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It GLP-1 weight loss meds + exercise seen preserving bone health Novo Nordisk's Wegovy gets the green light in China.
